Pharmacological Characterization of 1-(5-Chloro-6-(trifluoromethoxy)-1H-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic Acid (JNJ-42041935), a Potent and Selective Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor

Targeting HIF-1 for cancer therapy

Semenza, G. L. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1187 · Cited by 6,717 · see citing works

Targeting of HIF-α to the von Hippel-Lindau Ubiquitylation Complex by O ₂ -Regulated Prolyl Hydroxylation

Jaakkola, P., Mole, D. R., Tian, Y.-M., Wilson, M. I., Gielbert, J., Gaskell, S. J., Kriegsheim, A. V., Hebestreit, H. F., Mukherji, M., Schofield, C. J., et al. (2001) · Science · doi:10.1126/science.1059796 · Cited by 5,535 · see citing works

HIFα Targeted for VHL-Mediated Destruction by Proline Hydroxylation: Implications for O ₂ Sensing

Ivan, M., Kondo, K., Yang, H., Kim, W., Valiando, J., Ohh, M., Salic, A., Asara, J. M., Lane, W. S., & Kaelin Jr., W. G. (2001) · Science · doi:10.1126/science.1059817 · Cited by 4,735 · cited 10× · see citing works

C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation

Epstein, A. C. R., Gleadle, J. M., McNeill, L. A., Hewitson, K. S., O'Rourke, J., Mole, D. R., Mukherji, M., Metzen, E., Wilson, M. I., Dhanda, A., et al. (2001) · Cell · doi:10.1016/s0092-8674(01)00507-4 · Cited by 3,333 · see citing works

A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation

Semenza, G. L., & Wang, G. L. (1992) · Molecular and Cellular Biology · doi:10.1128/mcb.12.12.5447 · Cited by 2,617 · see citing works

A conserved family of prolyl-4-hydroxylases that modify HIF

Bruick, R. K., & McKnight, S. L. (2001) · Science · doi:10.1126/science.1066373 · Cited by 2,549 · see citing works

HIF prolyl‐hydroxylase 2 is the key oxygen sensor setting low steady‐state levels of HIF‐1α in normoxia

Berra, E., Benizri, E., Ginouvès, A., Volmat, V., Roux, D., & Pouysségur, J. (2003) · The EMBO Journal · doi:10.1093/emboj/cdg392 · Cited by 1,348 · see citing works

Forging a field: the golden age of iron biology.

Andrews, N. C. (2008) · Blood · doi:10.1182/blood-2007-12-077388 · Cited by 623 · see citing works

The Hydroxylase Inhibitor Dimethyloxalylglycine Is Protective in a Murine Model of Colitis

Cummins, E. P., Seeballuck, F., Keely, S. J., Mangan, N. E., Callanan, J. J., Fallon, P. G., & Taylor, C. T. (2008) · Gastroenterology · doi:10.1053/j.gastro.2007.10.012 · Cited by 407 · see citing works

Placental but Not Heart Defects Are Associated with Elevated Hypoxia-Inducible Factor α Levels in Mice Lacking Prolyl Hydroxylase Domain Protein 2

Takeda, K., Ho, V. C., Takeda, H., Duan, L.-J., Nagy, A., & Fong, G.-H. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.00425-06 · Cited by 401 · see citing works

Mucosal Protection by Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibition

Robinson, A., Keely, S., Karhausen, J., Gerich, M. E., Furuta, G. T., & Colgan, S. P. (2008) · Gastroenterology · doi:10.1053/j.gastro.2007.09.033 · Cited by 368 · see citing works

Cellular oxygen sensing: Crystal structure of hypoxia-inducible factor prolyl hydroxylase (PHD2)

McDonough, M. A., Li, V., Flashman, E., Chowdhury, R., Mohr, C., Liénard, B. M. R., Zondlo, J., Oldham, N. J., Clifton, I. J., Lewis, J. K., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0601283103 · Cited by 366 · see citing works

A family with erythrocytosis establishes a role for prolyl hydroxylase domain protein 2 in oxygen homeostasis

Percy, M. J., Zhao, Q., Flores, A., Harrison, C., Lappin, T. R. J., Maxwell, P. H., McMullin, M. F., & Lee, F. S. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0508423103 · Cited by 330 · see citing works

Mouse model for noninvasive imaging of HIF prolyl hydroxylase activity: assessment of an oral agent that stimulates erythropoietin production

Safran, M., Kim, W. Y., O'Connell, F., Flippin, L., Günzler, V., Horner, J. W., DePinho, R. A., & Kaelin, W. G. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0509459103 · Cited by 305 · see citing works

Regulation of adult erythropoiesis by prolyl hydroxylase domain proteins

Takeda, K., Aguila, H. L., Parikh, N. S., Li, X., Lamothe, K., Duan, L.-J., Takeda, H., Lee, F. S., & Fong, G.-H. (2008) · Blood · doi:10.1182/blood-2007-09-114561 · Cited by 263 · see citing works

Essential role for prolyl hydroxylase domain protein 2 in oxygen homeostasis of the adult vascular system

Takeda, K., Cowan, A., & Fong, G.-H. (2007) · Circulation · doi:10.1161/circulationaha.107.701516 · Cited by 236 · see citing works

Role of the hypoxia inducible factors HIF in iron metabolism

Peyssonnaux, C., Nizet, V., & Johnson, R. S. (2008) · Cell Cycle · doi:10.4161/cc.7.1.5145 · Cited by 217 · see citing works

Activation of the hypoxia‐inducible factor pathway and stimulation of angiogenesis by application of prolyl hydroxylase inhibitors

Warnecke, C., Griethe, W., Weidemann, A., Jürgensen, J. S., Willam, C., Bachmann, S., Ivashchenko, Y., Wagner, I., Frei, U. A., Wiesener, M., et al. (2003) · The FASEB Journal · doi:10.1096/fj.02-1062fje · Cited by 199 · see citing works

Transport of iron and other transition metals into cells as revealed by a fluorescent probe

Breuer, W., Epsztejn, S., Milgram, P., & Cabantchik, I. Z. (1995) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.1995.268.6.c1354 · Cited by 185 · see citing works

Developmental biology of erythropoiesis

Palis, J., & Segel, G. B. (1998) · Blood Reviews · doi:10.1016/s0268-960x(98)90022-4 · Cited by 170 · see citing works

Reactivation of hepatic EPO synthesis in mice after PHD loss

Minamishima, Y. A., & Kaelin, W. G. (2010) · Science · doi:10.1126/science.1192811 · Cited by 163 · see citing works

A novel erythrocytosis-associated PHD2 mutation suggests the location of a HIF binding groove

Percy, M. J., Furlow, P. W., Beer, P. A., Lappin, T. R. J., McMullin, M. F., & Lee, F. S. (2007) · Blood · doi:10.1182/blood-2007-04-084434 · Cited by 155 · see citing works

The antimycotic ciclopirox olamine induces HIF‐1α stability, VEGF expression, and angiogenesis

Linden, T., Katschinski, D. M., Eckhardt, K., Scheid, A., Pagel, H., & Wenger, R. H. (2003) · The FASEB Journal · doi:10.1096/fj.02-0586fje · Cited by 102 · see citing works

Utilization of an In Vivo Reporter for High Throughput Identification of Branched Small Molecule Regulators of Hypoxic Adaptation

Smirnova, N. A., Rakhman, I., Moroz, N., Basso, M., Payappilly, J. B., Kazakov, S. V., Hernandez-Guzman, F. G., Gaisina, I. N., Kozikowski, A. P., Ratan, R. R., et al. (2010) · Chemistry & Biology · doi:10.1016/j.chembiol.2010.03.008 · Cited by 75 · see citing works

Design and synthesis of a series of novel pyrazolopyridines as HIF 1-α prolyl hydroxylase inhibitors

Warshakoon, N. C., Wu, S., Boyer, A. S., Kawamoto, R. M., Renock, S., Xu, K., Pokross, M. E., Evdokimov, A. G., Zhou, S., Winter, C., et al. (2006) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2006.08.017 · Cited by 74 · see citing works

Kinetic characterization and identification of a novel inhibitor of hypoxia-inducible factor prolyl hydroxylase 2 using a time-resolved fluorescence resonance energy transfer-based assay technology

Dao, J. H., Kurzeja, R. J. M., Morachis, J. M., Veith, H., Lewis, J. K., Yu, V. L., Tegley, C. M., & Tagari, P. C. (2008) · Analytical Biochemistry · doi:10.1016/j.ab.2008.09.052 · Cited by 71 · see citing works

Benzimidazole-2-pyrazole HIF Prolyl 4-Hydroxylase Inhibitors as Oral Erythropoietin Secretagogues

Rosen, M. D., Venkatesan, H., Peltier, H. M., Bembenek, S. D., Kanelakis, K. C., Zhao, L. X., Leonard, B. E., Hocutt, F. M., Wu, X., Palomino, H. L., et al. (2010) · ACS Medicinal Chemistry Letters · doi:10.1021/ml100198y · Cited by 64 · see citing works

A novel series of imidazo[1,2-a]pyridine derivatives as HIF-1α prolyl hydroxylase inhibitors

Warshakoon, N. C., Wu, S., Boyer, A. S., Kawamoto, R. M., Sheville, J., Renock, S., Xu, K., Pokross, M. E., Evdokimov, A. G., Walter, R., et al. (2006) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2006.08.089 · Cited by 63 · see citing works

Clioquinol, a Cu(II)/Zn(II) Chelator, Inhibits Both Ubiquitination and Asparagine Hydroxylation of Hypoxia-inducible Factor-1α, Leading to Expression of Vascular Endothelial Growth Factor and Erythropoietin in Normoxic Cells

Choi, S., Choi, K.-O., Park, Y.-K., Cho, H.-J., Yang, E. G., & Park, H. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m603913200 · Cited by 59 · see citing works

Structure-based design, synthesis, and SAR evaluation of a new series of 8-hydroxyquinolines as HIF-1α prolyl hydroxylase inhibitors

Warshakoon, N. C., Wu, S., Boyer, A. S., Kawamoto, R. M., Sheville, J., Renock, S., Xu, K., Pokross, M. E., Zhou, S., Winter, C., et al. (2006) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2006.08.040 · Cited by 56 · see citing works

Disturbance in the HIF-1α pathway associated with erythrocytosis: Further evidences brought by frameshift and nonsense mutations in the prolyl hydroxylase domain protein 2 (PHD2) gene

Al-Sheikh, M., Moradkhani, K., Lopez, M., Wajcman, H., & Préhu, C. (2008) · Blood Cells Molecules and Diseases · doi:10.1016/j.bcmd.2007.07.017 · Cited by 50 · see citing works

Discovery of novel hydroxy-thiazoles as HIF-α prolyl hydroxylase inhibitors: SAR, synthesis, and modeling evaluation

Tegley, C. M., Viswanadhan, V. N., Biswas, K., Frohn, M. J., Peterkin, T. A. N., Chang, C. W. T., Bürli, R. W., Dao, J. H., Veith, H., Rogers, N. E., et al. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.06.031 · Cited by 45 · see citing works

Protracted anemia associated with chronic, relapsing systemic inflammation induced by arthropathic peptidoglycan-polysaccharide polymers in rats

Sartor, R. B., Anderle, S. K., Rifai, N., Goo, D. A. T., Cromartie, W. J., & Schwab, J. H. (1989) · Infection and Immunity · doi:10.1128/iai.57.4.1177-1185.1989 · Cited by 40 · see citing works

Design and synthesis of substituted pyridine derivatives as HIF-1α prolyl hydroxylase inhibitors

Warshakoon, N. C., Wu, S., Boyer, A. S., Kawamoto, R. M., Sheville, J., Bhatt, R. T., Renock, S., Xu, K., Pokross, M. E., Zhou, S., et al. (2006) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2006.08.026 · Cited by 39 · see citing works

Novel erythropoiesis stimulating protein (darbepoetin alfa) alleviates anemia associated with chronic inflammatory disease in a rodent model

Coccia, M. A., Cooke, K. S., Stoney, G., Pistillo, J., del Castillo, J. M. G., Duryea, D., Tarpley, J. E., & Molineux, G. (2001) · Experimental Hematology · doi:10.1016/s0301-472x(01)00723-8 · Cited by 29 · see citing works

Biochemical Characterization of Human Prolyl Hydroxylase Domain Protein 2 Variants Associated with Erythrocytosis

Pappalardi, M. B., Martin, J. D., Jiang, Y., Burns, M. C., Zhao, H., Ho, T. F., Sweitzer, S. M., Lor, L. A., Schwartz, B. J., Duffy, K. J., et al. (2008) · Biochemistry · doi:10.1021/bi801624f · Cited by 23 · see citing works

Characterization of a Robust Enzymatic Assay for Inhibitors of 2-Oxoglutarate-Dependent Hydroxylases

Kanelakis, K. C., Palomino, H. L., Li, L., Wu, J., Yan, W., Rosen, M. D., Rizzolio, M., Trivedi, M. V., Morton, M. F., Yang, Y., et al. (2009) · SLAS DISCOVERY · doi:10.1177/1087057109333976 · Cited by 14 · see citing works

Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials

Xie, X., Yu, T., Li, X., Zhang, N., Foster, L. J., Peng, C., Huang, W., & He, G. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01589-z · Cited by 396 · see citing works

Anaemia in kidney disease: harnessing hypoxia responses for therapy

Koury, M. J., & Haase, V. H. (2015) · Nature Reviews Nephrology · doi:10.1038/nrneph.2015.82 · Cited by 313 · see citing works

Regulation of IL-1β-induced NF-κB by hydroxylases links key hypoxic and inflammatory signaling pathways

Scholz, C. C., Cavadas, M. A. S., Tambuwala, M. M., Hams, E., Rodríguez, J., Kriegsheim, A. V., Cotter, P., Bruning, U., Fallon, P. G., Cheong, A., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1309718110 · Cited by 186 · see citing works

Prolyl Hydroxylase Inhibitors: A Breakthrough in the Therapy of Anemia Associated with Chronic Diseases

Joharapurkar, A. A., Pandya, V. B., Patel, V. J., Desai, R. C., & Jain, M. R. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b01686 · Cited by 170 · see citing works

Inhibition of Hypoxia-Inducible Factor Prolyl Hydroxylase Domain Oxygen Sensors: Tricking the Body into Mounting Orchestrated Survival and Repair Responses

Rabinowitz, M. H. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400386j · Cited by 165 · see citing works

Targeting the HIF pathway in inflammation and immunity

Scholz, C. C., & Taylor, C. T. (2013) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2013.04.009 · Cited by 155 · see citing works

Pharmacological targeting of the HIF hydroxylases – A new field in medicine development

Chan, M. C., Holt‐Martyn, J. P., Schofield, C. J., & Ratcliffe, P. J. (2016) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2016.01.001 · Cited by 126 · see citing works

Prolyl 4‐hydroxylases, master regulators of the hypoxia response

Myllyharju, J. (2013) · Acta Physiologica · doi:10.1111/apha.12096 · Cited by 118 · see citing works

A dynamic model of the hypoxia-inducible factor 1-alpha (HIF-1α) network

Nguyen, L. K., Cavadas, M. A. S., Scholz, C. C., Fitzpatrick, S. F., Brüning, U., Cummins, E. P., Tambuwala, M. M., Manresa, M. C., Kholodenko, B. Ν., Taylor, C. T., et al. (2013) · Journal of Cell Science · doi:10.1242/jcs.119974 · Cited by 113 · see citing works

Hif-1α–Induced Expression of Il-1β Protects against Mycobacterial Infection in Zebrafish

Ogryzko, N. V., Lewis, A., Wilson, H. L., Meijer, A. H., Renshaw, S. A., & Elks, P. M. (2018) · The Journal of Immunology · doi:10.4049/jimmunol.1801139 · Cited by 101 · see citing works

Substrate-Trapped Interactors of PHD3 and FIH Cluster in Distinct Signaling Pathways

Rodríguez, J., Pilkington, R., Muñoz, A. G., Nguyen, L. K., Rauch, N., Kennedy, S. A., Monsefi, N., Herrero, A., Taylor, C. T., & von Kriegsheim, A. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.02.043 · Cited by 95 · see citing works

Hypoxia and inflammatory bowel disease

Cummins, E. P., & Crean, D. (2016) · Microbes and Infection · doi:10.1016/j.micinf.2016.09.004 · Cited by 83 · see citing works

Hypoxia-inducible factor (HIF) network: insights from mathematical models

Cavadas, M. A. S., Nguyen, L. K., & Cheong, A. (2013) · Cell Communication and Signaling · doi:10.1186/1478-811x-11-42 · Cited by 75 · see citing works

Current strategies and progress for targeting the “undruggable” transcription factors

Zhuang, J., Liu, Q., Wu, D., & Tie, L. (2022) · Acta Pharmacologica Sinica · doi:10.1038/s41401-021-00852-9 · Cited by 72 · see citing works

Nonclinical Characterization of the Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat, a Novel Treatment of Anemia of Chronic Kidney Disease

del Balzo, U., Signore, P. E., Walkinshaw, G., Seeley, T. W., Brenner, M. C., Wang, Q., Guo, G., Arend, M., Flippin, L. A., Chow, F. A., et al. (2020) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.120.265181 · Cited by 70 · see citing works

1,3,8-Triazaspiro[4.5]decane-2,4-diones as Efficacious Pan-Inhibitors of Hypoxia-Inducible Factor Prolyl Hydroxylase 1–3 (HIF PHD1–3) for the Treatment of Anemia

Váchal, P., Miao, S., Pierce, J. M., Guiadeen, D., Colandrea, V. J., Wyvratt, M. J., Salowe, S. P., Sonatore, L. M., Milligan, J. A., Hajdu, R., et al. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm201542d · Cited by 67 · see citing works

Hypercapnia Suppresses the HIF-dependent Adaptive Response to Hypoxia

Selfridge, A. C., Cavadas, M. A. S., Scholz, C. C., Campbell, E. L., Welch, L. C., Lecuona, E., Colgan, S. P., Barrett, K. E., Sporn, P. H. S., Sznajder, J. I., et al. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.713941 · Cited by 67 · see citing works

Hypoxia-inducible factor 1 in clinical and experimental aortic aneurysm disease

Wang, W., Xu, B., Xuan, H., Ge, Y., Wang, Y., Wang, L., Huang, J., Fu, W., Michie, S. A., & Dalman, R. L. (2017) · Journal of Vascular Surgery · doi:10.1016/j.jvs.2017.09.030 · Cited by 67 · see citing works

Recent Advances in Developing Inhibitors for Hypoxia-Inducible Factor Prolyl Hydroxylases and Their Therapeutic Implications

Kim, S. Y., & Yang, E. (2015) · Molecules · doi:10.3390/molecules201119717 · Cited by 67 · see citing works

PHD3 Regulates p53 Protein Stability by Hydroxylating Proline 359

Rodríguez, J., Herrero, A., Li, S., Rauch, N., Quintanilla, A., Wynne, K. J., Krstić, A., Acosta, J. C., Taylor, C. T., Schlisio, S., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.06.108 · Cited by 62 · see citing works

Exploring the HIFs, buts and maybes of hypoxia signalling in disease: lessons from zebrafish models

Elks, P. M., Renshaw, S. A., Meijer, A. H., Walmsley, S. R., & van Eeden, F. J. (2015) · Disease Models & Mechanisms · doi:10.1242/dmm.021865 · Cited by 59 · see citing works

Transmembrane prolyl 4-hydroxylase is a fourth prolyl 4-hydroxylase regulating EPO production and erythropoiesis

Laitala, A., Aro, E., Walkinshaw, G., Mäki, J. M., Rossi, M., Heikkilä, M., Savolainen, E.-R., Arend, M., Kivirikko, K. I., Koivunen, P., et al. (2012) · Blood · doi:10.1182/blood-2012-07-441824 · Cited by 58 · see citing works

Discovery of N-[Bis(4-methoxyphenyl)methyl]-4-hydroxy-2-(pyridazin-3-yl)pyrimidine-5-carboxamide (MK-8617), an Orally Active Pan-Inhibitor of Hypoxia-Inducible Factor Prolyl Hydroxylase 1–3 (HIF PHD1–3) for the Treatment of Anemia

Debenham, J. S., Madsen-Duggan, C. B., Clements, M. J., Walsh, T. F., Kuethe, J. T., Reibarkh, M., Salowe, S. P., Sonatore, L. M., Hajdu, R., Milligan, J. A., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01242 · Cited by 56 · see citing works

Hypoxia Induces Macrophage tnfa Expression via Cyclooxygenase and Prostaglandin E2 in vivo

Lewis, A., & Elks, P. M. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02321 · Cited by 49 · see citing works

Prolyl hydroxylase inhibition corrects functional iron deficiency and inflammation‐induced anaemia in rats

Barrett, T. D., Palomino, H. L., Brondstetter, T. I., Kanelakis, K. C., Wu, X., Yan, W., Merton, K. P., Schoetens, F., Jing, Y., Skaptason, J., et al. (2015) · British Journal of Pharmacology · doi:10.1111/bph.13188 · Cited by 47 · see citing works

Interrogating the Druggability of the 2-Oxoglutarate-Dependent Dioxygenase Target Class by Chemical Proteomics

Joberty, G., Böesche, M., Brown, J. A., Eberhard, D., Garton, N. S., Humphreys, P. G., Mathieson, T., Muelbaier, M., Ramsden, N. G., Reader, V., et al. (2016) · ACS Chemical Biology · doi:10.1021/acschembio.6b00080 · Cited by 43 · see citing works

Roxadustat in the treatment of anaemia in chronic kidney disease

Vecchio, L. D., & Locatelli, F. (2017) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2018.1417386 · Cited by 43 · see citing works

Predation threats for a 24-h period activated the extension of axons in the brains of Xenopus tadpoles

Mori, T., Kitani, Y., Hatakeyama, D., Machida, K., Goto-Inoue, N., Hayakawa, S., Yamamoto, N., Kashiwagi, K., & Kashiwagi, A. (2020) · Scientific Reports · doi:10.1038/s41598-020-67975-7 · Cited by 40 · see citing works

Cell physiology regulation by hypoxia inducible factor-1: Targeting oxygen-related nanomachineries of hypoxic cells

Eskandani, M., Vandghanooni, S., Barar, J., Nazemiyeh, H., & Omidi, Y. (2017) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2016.10.113 · Cited by 38 · see citing works

Insight into Hypoxia Stemness Control

Mattia, M. D., Mauro, A., Citeroni, M. R., Dufrusine, B., Peserico, A., Russo, V., Berardinelli, P., Dainese, E., Cimini, A., & Barboni, B. (2021) · Cells · doi:10.3390/cells10082161 · Cited by 40 · see citing works

Hypoxia Downregulates MAPK/ERK but Not STAT3 Signaling in ROS‐Dependent and HIF‐1‐Independent Manners in Mouse Embryonic Stem Cells

Kučera, J., Netušilová, J., Sladeček, S., Lánová, M. K., Vašíček, O., Štefková, K., Navrátilová, J., Kubala, L., & Pachernı́k, J. (2017) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2017/4386947 · Cited by 35 · see citing works

HIF hydroxylase inhibitors decrease cellular oxygen consumption depending on their selectivity

Sulser, P., Pickel, C., Günter, J., Leissing, T. M., Crean, D., Schofield, C. J., Wenger, R. H., & Scholz, C. C. (2019) · The FASEB Journal · doi:10.1096/fj.201902240r · Cited by 30 · see citing works

Preclinical Characterization of Vadadustat (AKB-6548), an Oral Small Molecule Hypoxia-Inducible Factor Prolyl-4-Hydroxylase Inhibitor, for the Potential Treatment of Renal Anemia

Zuk, A., Si, Z., Loi, S., Bommegowda, S., Hoivik, D. J., Danthi, S. J., Molnar, G., Csizmadia, V., & Rabinowitz, M. H. (2022) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.122.001126 · Cited by 33 · see citing works

Hydroxylase inhibition regulates inflammation-induced intestinal fibrosis through the suppression of ERK-mediated TGF-β1 signaling

Manresa, M. C., Tambuwala, M. M., Radhakrishnan, P., Harnoss, J. M., Brown, E., Cavadas, M. A. S., Keogh, C. E., Cheong, A., Barrett, K. E., Cummins, E. P., et al. (2016) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00229.2016 · Cited by 28 · see citing works

Therapeutic inhibition of prolyl hydroxylase domain-containing enzymes in surgery: putative applications and challenges

Schneider, M., Harnoss, J. M., Strowitzki, M. J., Radhakrishnan, P., Platzer, L. K., Harnoss, J. C., Hank, T. P., Cai, J., & Ulrich, A. B. (2015) · Hypoxia · doi:10.2147/hp.s60872 · Cited by 26 · see citing works

Neuronal PAS Domain Protein 4 Suppression of Oxygen Sensing Optimizes Metabolism during Excitation of Neuroendocrine Cells

Sabatini, P. V., Speckmann, T., Nian, C., Glavas, M. M., Wong, C. K., Yoon, J. S., Kin, T., Shapiro, A. M. J., Gibson, W. T., Verchere, C. B., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2017.12.033 · Cited by 28 · see citing works

Angiopoietin‐like 4 promotes angiogenesis in the tendon and is increased in cyclically loaded tendon fibroblasts

Mousavizadeh, R., Scott, A., Lu, A., Ardekani, G. S., Behzad, H., Lundgreen, K., Ghaffari, M., McCormack, R. G., & Duronio, V. (2015) · The Journal of Physiology · doi:10.1113/jp271752 · Cited by 26 · see citing works

Pharmacologic inhibition of hypoxia‐inducible factor (HIF)‐hydroxylases ameliorates allergic contact dermatitis

Manresa, M. C., Smith, L., Casals‐Diaz, L., Fagundes, R. R., Brown, E., Radhakrishnan, P., Murphy, S. J., Crifò, B., Strowitzki, M. J., Halligan, D. N., et al. (2018) · Allergy · doi:10.1111/all.13655 · Cited by 25 · see citing works

Hypoxia Reduces the Pathogenicity of Pseudomonas aeruginosa by Decreasing the Expression of Multiple Virulence Factors

Schaible, B., Rodríguez, J., García, A. S., von Kriegsheim, A., McClean, S., Hickey, C., Keogh, C. E., Brown, E., Schaffer, K., Broquet, A. H., et al. (2017) · The Journal of Infectious Diseases · doi:10.1093/infdis/jix139 · Cited by 25 · see citing works

Neuroprotective strategies for acute ischemic stroke: Targeting oxidative stress and prolyl hydroxylase domain inhibition in synaptic signalling

Puzio, M., Moreton, N., & O'Connor, J. J. (2022) · Brain Disorders · doi:10.1016/j.dscb.2022.100030 · Cited by 23 · see citing works

Paricalcitol protects against TGF-β1-induced fibrotic responses in hypoxia and stabilises HIF-α in renal epithelia

Nolan, K. A., Brennan, E. P., Scholz, C. C., Cullen, C., Ryan, A., Taylor, C. T., & Godson, C. (2014) · Experimental Cell Research · doi:10.1016/j.yexcr.2014.07.034 · Cited by 23 · see citing works

The stabilization of hypoxia inducible factor modulates differentiation status and inhibits the proliferation of mouse embryonic stem cells

Binó, L., Kučera, J., Štefková, K., Sindlerova, L. S., Lánová, M. K., Kudová, J., Kubala, L., & Pachernı́k, J. (2015) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2015.12.007 · Cited by 23 · see citing works

Sensing an Oxygen Sensor: Development and Application of Activity-Based Assays Directly Monitoring HIF Heterodimerization

Janssens, L. K., & Stove, C. P. (2021) · Analytical Chemistry · doi:10.1021/acs.analchem.1c02923 · Cited by 22 · see citing works

Inhibition of prolyl hydroxylases alters cell metabolism and reverses pre-existing diastolic dysfunction in mice

He, X., Zeng, H., Roman, R. J., & Chen, J. (2018) · International Journal of Cardiology · doi:10.1016/j.ijcard.2018.08.065 · Cited by 18 · see citing works

DMOG, a Prolyl Hydroxylase Inhibitor, Increases Hemoglobin Levels without Exacerbating Hypertension and Renal Injury in Salt-Sensitive Hypertensive Rats

Kato, S., Takahashi, T., Miyata, N., & Roman, R. J. (2019) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.119.262782 · Cited by 18 · see citing works

Pyrazole‐4‐carboxylic Acids from Vanadium‐catalyzed Chemical Transformation of Pyrazole‐4‐carbaldehydes

Bala, R., Kumari, P., Sood, S., Phougat, H., Kumar, A., & Singh, K. (2019) · Journal of Heterocyclic Chemistry · doi:10.1002/jhet.3546 · Cited by 18 · see citing works

Efficacy and Safety of Daprodustat for Anemia Therapy in Chronic Kidney Disease Patients: A Systematic Review and Meta-Analysis

Zheng, Q., Wang, Y., Yang, H., Sun, L., Fu, X., Wei, R., Liu, Y., & Liu, W. J. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.573645 · Cited by 16 · see citing works

Structure-based drug design for hypoxia-inducible factor prolyl-hydroxylase inhibitors and its therapeutic potential for the treatment of erythropoiesis-stimulating agent-resistant anemia: raising expectations for exploratory clinical trials

Higashijima, Y., Tanaka, T., & Nangaku, M. (2013) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2013.796358 · Cited by 14 · see citing works

Treatment with the Prolyl Hydroxylase Inhibitor JNJ Promotes Abdominal Aortic Aneurysm Progression in Diabetic Mice

Guo, J., Shoji, T., Ge, Y., Zheng, X., Li, Y., Zhao, S., Ikezoe, T., Liu, S., Huang, J., Wang, W., et al. (2021) · European Journal of Vascular and Endovascular Surgery · doi:10.1016/j.ejvs.2021.10.030 · Cited by 13 · see citing works

Associations between HIFs and tumor immune checkpoints: mechanism and therapy

Liu, J., Jiang, Y., Chen, L., Qian, Z., & Zhang, Y. (2024) · Discover Oncology · doi:10.1007/s12672-023-00836-7 · Cited by 13 · see citing works

Cardiovascular risk in chronic kidney disease: what is new in the pathogenesis and treatment?

Bielach-Bazyluk, A., Małyszko, J., & Zbroch, E. (2018) · Postgraduate Medicine · doi:10.1080/00325481.2018.1481714 · Cited by 13 · see citing works

Small-molecule inhibitors of HIF-PHD2: a valid strategy to renal anemia treatment in clinical therapy

Wu, Y., Wang, N., Lei, Y., Hu, T., You, Q., & Zhang, X. (2016) · MedChemComm · doi:10.1039/c6md00240d · Cited by 13 · see citing works

Inhibition of firefly luciferase activity by a HIF prolyl hydroxylase inhibitor

Günter, J., Wenger, R. H., & Scholz, C. C. (2020) · Journal of Photochemistry and Photobiology B Biology · doi:10.1016/j.jphotobiol.2020.111980 · Cited by 12 · see citing works

Molecular exploration of natural and synthetic compounds databases for promising hypoxia inducible factor (HIF) Prolyl-4- hydroxylase domain (PHD) inhibitors using molecular simulation and free energy calculations

Sayaf, A. M., Kousar, K., Suleman, M., Albekairi, N. A., Alshammari, A., Mohammad, A., Khan, A., Agouni, A., & Yeoh, K. K. (2024) · BMC Chemistry · doi:10.1186/s13065-024-01347-4 · Cited by 11 · see citing works

The effects of prolyl hydroxylase inhibition during and post, hypoxia, oxygen glucose deprivation and oxidative stress, in isolated rat hippocampal slices

Moreton, N., Puzio, M., McCormack, J., & O'Connor, J. J. (2023) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2023.110822 · Cited by 10 · see citing works

AURKB, in concert with REST, acts as an oxygen-sensitive epigenetic regulator of the hypoxic induction of MDM2

Kim, I., Choi, S., Yoo, S., Lee, M., & Park, J. (2022) · BMB Reports · doi:10.5483/bmbrep.2022.55.6.017 · Cited by 9 · see citing works

Time-dependent inhibition of PHD2

Tcholakov, I., Grimshaw, C. E., Shi, L., Kiryanov, A. A., Murphy, S. T., Larson, C. J., Płonowski, A., & Ermolieff, J. (2017) · Bioscience Reports · doi:10.1042/bsr20170275 · Cited by 8 · see citing works

Furan- and Thiophene-2-Carbonyl Amino Acid Derivatives Activate Hypoxia-Inducible Factor via Inhibition of Factor Inhibiting Hypoxia-Inducible Factor-1

Kawaguchi, S., Gonda, Y., Yamamoto, T., Sato, Y., Shinohara, H., Kobiki, Y., Ichimura, A., Dan, T., Sonoda, M., Miyata, T., et al. (2018) · Molecules · doi:10.3390/molecules23040885 · Cited by 8 · see citing works

Genetic Knockdown and Pharmacologic Inhibition of Hypoxia-Inducible Factor (HIF) Hydroxylases

Pickel, C., Taylor, C. T., & Scholz, C. C. (2018) · Methods in molecular biology · doi:10.1007/978-1-4939-7665-2_1 · Cited by 7 · see citing works

Beyond Traditional Structure-Based Drug Design: The Role of Iron Complexation, Strain, and Water in the Binding of Inhibitors for Hypoxia-Inducible Factor Prolyl Hydroxylase 2

Bembenek, S. D., Venkatesan, H., Peltier, H. M., Rosen, M. D., Barrett, T. D., Kanelakis, K. C., Palomino, H. L., Brondstetter, T. I., Mirzadegan, T., & Rabinowitz, M. H. (2019) · ACS Omega · doi:10.1021/acsomega.9b00199 · Cited by 7 · see citing works

Saos‐2 cells cultured under hypoxia rapidly differentiate to an osteocyte‐like stage and support intracellular infection by Staphylococcus aureus

Zelmer, A. R., Starczak, Y., Solomon, L. B., Richter, K., Yang, D., & Atkins, G. J. (2023) · Physiological Reports · doi:10.14814/phy2.15851 · Cited by 7 · see citing works

Profiling Inhibitor Scaffolds for the Cancer Target Jumonji‐C Domain‐Containing Protein 6

Corner, T. P., Salah, E., Tumber, A., Holt‐Martyn, J. P., Brewitz, L., & Schofield, C. J. (2025) · ChemMedChem · doi:10.1002/cmdc.202500682 · Cited by 6 · see citing works

Control of the heart rate of rat embryos during the organogenic period

Ritchie, H. E., Ragnerstam, C., Gustafsson, E., Jonsson, J. M., & Webster, W. S. (2016) · Hypoxia · doi:10.2147/hp.s115050 · Cited by 3 · see citing works

Inhibition of prolyl hydroxylase domain proteins selectively enhances venous thrombus neovascularisation

Grover, S. P., Saha, P., Humphries, J., Lyons, O., Patel, A. S., Serneels, J., Modarai, B., Mazzone, M., & Smith, A. (2018) · Thrombosis Research · doi:10.1016/j.thromres.2018.07.015 · Cited by 3 · see citing works

Copper-Catalyzed Synthesis, Bio-Evaluation, and in Silico Studies of 2-Aryl-N-alkylbenzimidazoles as Neuroprotective Agents

Yao, Y., Jia, N.-N., Cao, Y.-N., Chen, X., Gao, F., & Liang, X.-X. (2018) · Catalysts · doi:10.3390/catal8100433 · Cited by 3 · see citing works

A Review on Pyrazole Derivatives Used in the Treatment of Rheumatoid Arthritis: Recent Advancement and Drug Development

Chaudhary, N., & Sharma, N. (2024) · Current Rheumatology Reviews · doi:10.2174/0115733971267325231227092819 · Cited by 2 · see citing works

Azole derivatives as novel non-iron-chelating inhibitors of prolyl hydroxylase 3 for HIF-1 activation

Cao, J., Ma, X., Wang, X., Wang, X., Zhang, Z., Geng, Z., & Wang, Z. (2013) · MedChemComm · doi:10.1039/c3md00117b · Cited by 2 · see citing works

TP0463518 (TS-143) Ameliorates Peptidoglycan-Polysaccharide Induced Anemia of Inflammation in Rats

Kato, S., Yamamoto, K., Uchida, S., & Takahashi, T. (2021) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b21-00038 · Cited by 1 · see citing works

A Patent Review on Thiazole Derivatives (2008-2013)

Leoni, A., Aless, Locatelli, R., Morigi, R., & Rambaldi, M. (2017) · Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) · Cited by 1 · see citing works

ANEMIA OF CHRONIC KIDNEY DISEASE: NOVEL PHYSIOLOGICAL APPROACHES TO THERAPY BASED ON SIMULATION OF HYPOXIC RESPONSE

Айтбаев, К. А., Murkamilov, I. T., & Fomin, V. V. (2017) · Almanac of Clinical Medicine · doi:10.18786/2072-0505-2017-45-7-565-574 · Cited by 1 · see citing works

Hif-1α stabilisation polarises macrophages via cyclooxygenase/prostaglandin E2 in vivoPreprint

Lewis, A., & Elks, P. M. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/536862 · Cited by 1 · see citing works

Culture of Saos-2 cells under hypoxic conditions stimulates rapid differentiation to an osteocyte-like stagePreprint

Zelmer, A. R., Starczak, Y., Solomon, L. B., Richter, K., Yang, D., & Atkins, G. J. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.04.23.537998 · Cited by 1 · see citing works

Rescuing the Function of Missense-Mutated Tumor Suppressor VHL using Stabilizing Small MoleculesPreprint

Fouad, M. A., Parry, C. S., Miller, S. A., Malhotra, S., Doyle, G. A. R., Shimabenga, E., Nurilloeva, M., Bondarenko, E., Andrianov, G. V., Childers, W. E., et al. (2026) · eLife · doi:10.7554/elife.110305.2 · Cited by 1 · see citing works

Rescuing the Function of Missense-Mutated Tumor Suppressor VHL using Stabilizing Small MoleculesPreprint

Fouad, M. A., Parry, C. S., Miller, S. A., Malhotra, S., Doyle, G. A. R., Shimabenga, E., Nurilloeva, M., Bondarenko, E., Andrianov, G. V., Childers, W., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.01.02.697373

Rescuing the Function of Missense-Mutated Tumor Suppressor VHL using Stabilizing Small MoleculesPreprint

Fouad, M. A., Parry, C. S., Miller, S. A., Malhotra, S., Doyle, G. A. R., Shimabenga, E., Nurilloeva, M., Bondarenko, E. A., Andrianov, G. V., Childers, W. E., et al. (2026) · eLife · doi:10.7554/elife.110305.1

Rescuing the Function of Missense-Mutated Tumor Suppressor VHL using Stabilizing Small MoleculesPreprint

Fouad, M. A., Parry, C. S., Miller, S. A., Malhotra, S., Doyle, G. A. R., Shimabenga, E., Nurilloeva, M., Bondarenko, E. A., Andrianov, G. V., Childers, W. E., et al. (2026) · eLife · doi:10.7554/elife.110305

Characterization of Novel Metabolites of the HIF Stabilizer JNJ‐42041935 in Rats Using LC‐HRMS for Doping Control Purposes: A Pilot Study

Hou, J., & Yang, S. (2026) · Drug Testing and Analysis · doi:10.1002/dta.70086

Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors: Mechanisms, Therapeutic Applications, and Developmental Progress

Fangyu, Y., & Shuangquan, K. (2026) · Kidney Medicine · doi:10.1016/j.xkme.2026.101472

BindingDB Entry 50039890: 1,3,8-Triazaspiro[4.5]decane-2,4-diones as efficacious pan-inhibitors of hypoxia-inducible factor prolyl hydroxylase 1-3 (HIF PHD1-3) for the treatment of anemia.

BindingDB (2013) · UC San Diego · doi:10.7270/q27945qw

BindingDB Entry 50001712: Prolyl Hydroxylase Inhibitors: A Breakthrough in the Therapy of Anemia Associated with Chronic Diseases.

BindingDB (2020) · UC San Diego · doi:10.7270/q2h70jc7

BindingDB Entry 50013236: Discovery of N-[Bis(4-methoxyphenyl)methyl]-4-hydroxy-2-(pyridazin-3-yl)pyrimidine-5-carboxamide (MK-8617), an Orally Active Pan-Inhibitor of Hypoxia-Inducible Factor Prolyl Hydroxylase 1-3 (HIF PHD1-3) for the Treatment of Anemia.

BindingDB (2022) · UC San Diego · doi:10.7270/q2br8wwr

BindingDB Entry 50043829: Inhibition of hypoxia-inducible factor prolyl hydroxylase domain oxygen sensors: tricking the body into mounting orchestrated survival and repair responses.

BindingDB (2014) · UC San Diego · doi:10.7270/q290258t

Discovery of JTZ-951: A HIF Prolyl Hydroxylase Inhibitor for the Treatment of Renal Anemia

Ogoshi, Y., Matsui, T., Mitani, I., Yokota, M., Terashita, M., Motoda, D., Ueyama, K., Hotta, T., Ito, T., Hase, Y., et al. (2017) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.7b00404 · Cited by 56 · see citing works

Inhibition of firefly luciferase activity by a HIF prolyl hydroxylase inhibitor

Günter, J., Wenger, R. H., & Scholz, C. C. (2020) · Journal of Photochemistry and Photobiology B Biology · doi:10.1016/j.jphotobiol.2020.111980 · Cited by 12 · see citing works

Structure‐Activity Relationship and Crystallographic Studies on 4‐Hydroxypyrimidine HIF Prolyl Hydroxylase Domain Inhibitors

Holt‐Martyn, J. P., Chowdhury, R., Tumber, A., Yeh, T., Abboud, M. I., Lippl, K., Lohans, C. T., Langley, G. W., Figg, W. D., McDonough, M. A., et al. (2019) · ChemMedChem · doi:10.1002/cmdc.201900557 · Cited by 33 · see citing works

Discovery of Novel and Potent Prolyl Hydroxylase Domain-Containing Protein (PHD) Inhibitors for The Treatment of Anemia

Xu, J., Ding, X., Fu, Y., Meng, Q., Wang, L., Zhang, M., Xu, C., Chen, S., Aliper, A., Ren, F., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c01932 · Cited by 11 · see citing works

Benzimidazole-2-pyrazole HIF Prolyl 4-Hydroxylase Inhibitors as Oral Erythropoietin Secretagogues

Rosen, M. D., Venkatesan, H., Peltier, H. M., Bembenek, S. D., Kanelakis, K. C., Zhao, L. X., Leonard, B. E., Hocutt, F. M., Wu, X., Palomino, H. L., et al. (2010) · ACS Medicinal Chemistry Letters · doi:10.1021/ml100198y · Cited by 64 · see citing works